The primary analysis of Maestro-Nash had always relied on Nafld activity score, with a controversial trial entry change just a “typo”, the company says.
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
A hit on one goal helps, but future Nash data will be more decisive.
The company follows Madrigal and Akero with a clinical hit.
The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.
Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.